Fig. 3.

Use of Oncotype DX improves survival. A Hazard ratio of Oncotype DX usage between 2004 and 2015 from univariate and multivariable Cox models. Multivariable Cox models were adjusted for tumor stage, tumor grade, lymph node status, breast cancer subtype (ER+HER2− or ER+HER2+), and patients’ age. B Hazard ratios of Oncotype DX usage stratified by tumor stage between 2004 and 2015 from univariate Cox regression models. C Hazard ratio of Oncotype DX usage stratified by subtypes between 2010 and 2015 from univariate Cox regression models. D Hazard ratio of Oncotype DX usage stratified by lymph node status between 2004 and 2015 from univariate Cox regression models. P values below 0.05 were considered significant